Serum levels of advanced glycation end products negatively correlates with activity of Paraoxonase1 and Lecithin-Cholesterol Acyltransferase in diabetic retinopathy; A cross-sectional case-control study
{"title":"Serum levels of advanced glycation end products negatively correlates with activity of Paraoxonase1 and Lecithin-Cholesterol Acyltransferase in diabetic retinopathy; A cross-sectional case-control study","authors":"Akram Arabi , Soghra Rabizadeh , Saeed Mirmoosavi , Hossein Mirmiranpour , Firouzeh Heidari , Fatemeh Mohammadi , Alireza Esteghamati , Manouchehr Nakhjavani","doi":"10.1016/j.clinbiochem.2025.110925","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Development of diabetic retinopathy (DR) is closely linked to oxidative stress triggered by various metabolic pathways. Paraoxonase 1 (PON1) and Lecithin-Cholesterol Acyltransferase (LCAT) have protective roles in DR that remain poorly understood. Higher AGEs levels and its role in vascular complications of type 2 diabetes has been shown in previous studies. This case-control study aimed to assess LCAT and PON1 activity and their correlation with advanced glycation end products (AGEs) in patients with diabetes with or without retinopathy.</div></div><div><h3>Method</h3><div>45 healthy individuals and 88 diabetic patients were enrolled, categorized as No Diabetic Retinopathy (NDR), Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR).</div></div><div><h3>Results</h3><div>PON1 and LCAT activity conversely correlated with serum levels of advanced glycation end products in patients with diabetic retinopathy. There was not such a correlation in patients without DR nor in controls. The correlation was stronger between PON1 and AGEs in comparison to LCAT.</div><div>PON1 activity was significantly lower in type 2 diabetes patients compared to healthy controls (45.39 ± 16.48 and 203.75 ± 8.92, respectively, P < 0.001). Activity further decreased in NPDR and PDR compared to NDR (23.99 ± 9.79 and 21.28 ± 8.22, respectively, P < 0.001). LCAT activity was significantly lower in diabetic patients compared to controls (33.16 ± 5.98 and 44.35 ± 2.26, respectively, P < 0.001). However, LCAT activity was not lower in diabetic retinopathy compared to NDR (P > 0.05).</div></div><div><h3>Conclusion</h3><div>Serum PON1 activity negatively correlated with AGEs levels in patients with diabetes but not in controls. The LCAT-AGEs correlation however was only significant in PDR patients. These findings emphasize the potential importance of AGES and PON1 in diabetic retinopathy development and progression.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"137 ","pages":"Article 110925"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009912025000542","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Development of diabetic retinopathy (DR) is closely linked to oxidative stress triggered by various metabolic pathways. Paraoxonase 1 (PON1) and Lecithin-Cholesterol Acyltransferase (LCAT) have protective roles in DR that remain poorly understood. Higher AGEs levels and its role in vascular complications of type 2 diabetes has been shown in previous studies. This case-control study aimed to assess LCAT and PON1 activity and their correlation with advanced glycation end products (AGEs) in patients with diabetes with or without retinopathy.
Method
45 healthy individuals and 88 diabetic patients were enrolled, categorized as No Diabetic Retinopathy (NDR), Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR).
Results
PON1 and LCAT activity conversely correlated with serum levels of advanced glycation end products in patients with diabetic retinopathy. There was not such a correlation in patients without DR nor in controls. The correlation was stronger between PON1 and AGEs in comparison to LCAT.
PON1 activity was significantly lower in type 2 diabetes patients compared to healthy controls (45.39 ± 16.48 and 203.75 ± 8.92, respectively, P < 0.001). Activity further decreased in NPDR and PDR compared to NDR (23.99 ± 9.79 and 21.28 ± 8.22, respectively, P < 0.001). LCAT activity was significantly lower in diabetic patients compared to controls (33.16 ± 5.98 and 44.35 ± 2.26, respectively, P < 0.001). However, LCAT activity was not lower in diabetic retinopathy compared to NDR (P > 0.05).
Conclusion
Serum PON1 activity negatively correlated with AGEs levels in patients with diabetes but not in controls. The LCAT-AGEs correlation however was only significant in PDR patients. These findings emphasize the potential importance of AGES and PON1 in diabetic retinopathy development and progression.
期刊介绍:
Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.